249 related articles for article (PubMed ID: 15177518)
1. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome.
Nashar K; Nguyen JP; Jesri A; Morrow JD; Egan BM
Am J Hypertens; 2004 Jun; 17(6):477-82. PubMed ID: 15177518
[TBL] [Abstract][Full Text] [Related]
2. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
[TBL] [Abstract][Full Text] [Related]
3. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
[TBL] [Abstract][Full Text] [Related]
4. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
Sharma AM; Wagner T; Marsalek P
J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
[TBL] [Abstract][Full Text] [Related]
5. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
Krupicka J; Ceypová K; Kristenová P; Hauser T
Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
[TBL] [Abstract][Full Text] [Related]
6. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.
Spinar J; Vítovec J; Soucek M; Dusek L; Pavlík T;
Vnitr Lek; 2009 May; 55(5):481-8. PubMed ID: 19514614
[TBL] [Abstract][Full Text] [Related]
7. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension.
Fagard R; Lijnen P; Pardaens K; Thijs L; Vinck W
J Hum Hypertens; 2001 Mar; 15(3):161-7. PubMed ID: 11317199
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure.
Egan BM; Papademetriou V; Wofford M; Calhoun D; Fernandes J; Riehle JE; Nesbitt S; Michelson E; Julius S;
Am J Hypertens; 2005 Jan; 18(1):3-12. PubMed ID: 15691610
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
Ellis D; Moritz ML; Vats A; Janosky JE
Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
[TBL] [Abstract][Full Text] [Related]
12. [Profile on circadian blood pressure and the influencing factors in essential hypertensive patients after treatment].
Qiu YG; Yao XY; Tao QM; Zheng P; Chen JZ; Zhu JH; Zhang FR; Zheng LR; Zhao LL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Aug; 25(8):710-4. PubMed ID: 15555399
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
14. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Lazzari P; Derosa G
Horm Metab Res; 2010 Nov; 42(12):892-6. PubMed ID: 20814848
[TBL] [Abstract][Full Text] [Related]
15. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
[TBL] [Abstract][Full Text] [Related]
16. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension.
Park JB; Intengan HD; Schiffrin EL
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):40-5. PubMed ID: 11967798
[TBL] [Abstract][Full Text] [Related]
17. Too old to benefit from sports? The cardiovascular effects of exercise training in elderly subjects treated for isolated systolic hypertension.
Westhoff TH; Franke N; Schmidt S; Vallbracht-Israng K; Meissner R; Yildirim H; Schlattmann P; Zidek W; Dimeo F; van der Giet M
Kidney Blood Press Res; 2007; 30(4):240-7. PubMed ID: 17575470
[TBL] [Abstract][Full Text] [Related]
18. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system.
Iglarz M; Touyz RM; Viel EC; Amiri F; Schiffrin EL
Am J Hypertens; 2004 Jul; 17(7):597-603. PubMed ID: 15243979
[TBL] [Abstract][Full Text] [Related]
19. Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension.
Wu G; Tian H; Han K; Xi Y; Yao Y; Ma A
Clin Exp Hypertens; 2006 Jul; 28(5):489-97. PubMed ID: 16820345
[TBL] [Abstract][Full Text] [Related]
20. Effect of losartan therapy on endothelial function in hypertensive patients.
Sosa-Canache B; Hernández-Hernández R; Armas-Padilla MC; Armas-Hernández MJ; Cammarata-Segura R; Pacheco B; Guerrero J; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):166-71. PubMed ID: 17414585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
